Commentary
Recently published articles about Commentary
Commentary
Beyond the Boxed Warning: A Call for Regulation of Psychiatry’s Most Teratogenic Drug
October 6, 2025
The authors assert that while valproate remains invaluable for certain severe conditions, the high risk of teratogenicity means stringent safeguards are needed to regulate its use by individuals capable...
Commentary
Prioritizing Mental Health to Optimize Perinatal, Fetal, and Neonatal Outcomes
September 24, 2025
Following an FDA panel discussion on use of SSRIs in pregnancy, the authors highlight the need for balanced conversations and shared decision-making accounting for the risks of untreated disease...
Commentary
Practitioners Providing Care for Persons with Severe Mental Disorders Should Routinely Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease
September 10, 2025
Persons with severe mental illnesses should be routinely screened for MASLD as part of a psychiatric and medical assessment that includes social and economic determinants of health, risk factors...
Recent JCP Articles on Commentary
Case Series
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
November 3, 2025
Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
Recent PCC Articles on Commentary
Case Report
Cerebrotendinous Xanthomatosis: Unraveling Prominent Neuropsychiatric Symptoms and Mild Cognitive Impairment With Subsequent Clinical Improvement
October 30, 2025
A 51-year-old woman who exhibited an 8-month history of significant cognitive decline and behavioral changes, including forgetfulness, irritability, and anger outbursts, leading to an initial diagnosis of mild neurocognitive...
